-
公开(公告)号：US20050186261A1
公开(公告)日：2005-08-25
申请号：US11048628
申请日：2005-01-31
申请人： Rui Avelar , Richard Liggins , Philip Toleikis , Troy Loss , David Gravett , Arpita Maiti
发明人： Rui Avelar , Richard Liggins , Philip Toleikis , Troy Loss , David Gravett , Arpita Maiti
IPC分类号： A61K31/335 , A61K31/337 , A61K31/407 , A61K31/4745 , A61K31/704 , A61K31/7048 , A61K31/7072
CPC分类号： A61K31/335 , A61K9/0024 , A61K9/06 , A61K9/1075 , A61K9/1652 , A61K9/1658 , A61K47/10 , A61K47/34 , A61K47/36
摘要： A method for treating contracture is provided that includes administering to a patient in need thereof a composition that includes a therapeutic agent effective in treating contracture. Compositions, devices, and kits for use in treating contracture are also described.
摘要翻译： 提供了一种治疗挛缩的方法，其包括向有需要的患者施用包含有效治疗挛缩的治疗剂的组合物。 还描述了用于治疗挛缩的组合物，装置和试剂盒。
-
公开(公告)号：US20050186247A1
公开(公告)日：2005-08-25
申请号：US11006904
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61B17/68 , A61C5/00 , A61F2/00 , A61F2/28 , A61F13/00 , A61K31/045 , A61K31/4745 , A61K31/513 , A61K31/525 , A61K31/65 , A61K31/70 , A61K31/7012 , A61K31/704 , A61K31/7048 , A61K31/7072 , A61K31/765 , A61K33/14 , A61K33/24 , A61K38/17 , A61K38/18 , A61K38/19 , A61K38/20 , A61K38/24 , A61K38/39 , A61K38/48 , A61K49/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16
CPC分类号： A61L27/54 , A61B17/11 , A61B17/12022 , A61B17/12099 , A61B17/12109 , A61B17/1214 , A61B17/12168 , A61B17/12186 , A61B17/1219 , A61B17/68 , A61F2250/0067 , A61K38/363 , A61K38/38 , A61K38/39 , A61K38/4833 , A61K45/06 , A61L31/16 , A61L2300/00 , A61L2300/412 , A61L2430/38 , A61K2300/00
摘要： Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
-
公开(公告)号：US20050183731A1
公开(公告)日：2005-08-25
申请号：US11006908
申请日：2004-12-07
申请人： William Hunter , Philip Toleikis , David Gravett , Arpita Maiti , Richard Liggins , Aniko Takacs-Cox , Rui Avelar , Troy Loss
发明人： William Hunter , Philip Toleikis , David Gravett , Arpita Maiti , Richard Liggins , Aniko Takacs-Cox , Rui Avelar , Troy Loss
IPC分类号： A61B19/00 , A61F2/00 , A61F2/08 , A61F2/28 , A61F2/44 , A61K9/14 , A61K31/337 , A61K31/365 , A61K31/4745 , A61K31/704 , A61K31/7048 , A61K31/7072 , A61K38/00 , A61L27/54 , A61L31/16 , A61M31/00 , A61N1/00 , A61N1/05
CPC分类号： A61K45/06 , A61L27/54 , A61L31/16 , A61L2300/404 , A61L2300/416 , A61L2300/432
摘要： Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
-
公开(公告)号：US20050183728A1
公开(公告)日：2005-08-25
申请号：US11007836
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61F2/00 , A61F2/02 , A61F2/04 , A61F2/06 , A61F2/28 , A61F2/44 , A61K38/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M16/04 , A61M31/00 , A61N1/05 , A62B9/00
CPC分类号： A61L31/16 , A61B17/11 , A61B17/12022 , A61B17/1219 , A61F2250/0067 , A61L2300/404 , A61L2300/406 , A61L2300/416 , A61L2300/426 , A61L2300/432 , A61N1/05
摘要： Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
-
公开(公告)号：US20050181011A1
公开(公告)日：2005-08-18
申请号：US11001792
申请日：2004-12-02
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61F2/00 , A61F2/02 , A61F2/04 , A61F2/06 , A61F2/28 , A61F2/44 , A61K38/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M16/04 , A61M31/00 , A61N1/05 , A62B9/00
CPC分类号： A61L31/16 , A61B17/11 , A61B17/12022 , A61B17/1219 , A61F2250/0067 , A61L2300/404 , A61L2300/406 , A61L2300/416 , A61L2300/426 , A61L2300/432 , A61N1/05
摘要： Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
-
公开(公告)号：US20050175703A1
公开(公告)日：2005-08-11
申请号：US11006888
申请日：2004-12-07
申请人： William Hunter , Philip Toleikis , David Gravett , Arpita Maiti , Richard Liggins , Aniko Takacs-Cox , Rui Avelar , Troy Loss
发明人： William Hunter , Philip Toleikis , David Gravett , Arpita Maiti , Richard Liggins , Aniko Takacs-Cox , Rui Avelar , Troy Loss
IPC分类号： A61B19/00 , A61F2/00 , A61F2/08 , A61F2/28 , A61F2/44 , A61K9/14 , A61K31/337 , A61K31/365 , A61K31/4745 , A61K31/704 , A61K31/7048 , A61K31/7072 , A61K38/00 , A61L27/54 , A61L31/16 , A61M31/00 , A61N1/00 , A61N1/05
CPC分类号： A61K45/06 , A61L27/54 , A61L31/16 , A61L2300/404 , A61L2300/416 , A61L2300/432
摘要： Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
-
公开(公告)号：US20050175665A1
公开(公告)日：2005-08-11
申请号：US11006896
申请日：2004-12-07
申请人： William Hunter , Philip Toleikis , David Gravett , Arpita Maiti , Richard Liggins , Aniko Takacs-Cox , Rui Avelar , Troy Loss
发明人： William Hunter , Philip Toleikis , David Gravett , Arpita Maiti , Richard Liggins , Aniko Takacs-Cox , Rui Avelar , Troy Loss
IPC分类号： A61B19/00 , A61F2/00 , A61F2/08 , A61F2/28 , A61F2/44 , A61K9/14 , A61K31/337 , A61K31/365 , A61K31/4745 , A61K31/704 , A61K31/7048 , A61K31/7072 , A61K38/00 , A61L27/54 , A61L31/16 , A61M31/00 , A61N1/00 , A61N1/05
CPC分类号： A61K45/06 , A61L27/54 , A61L31/16 , A61L2300/404 , A61L2300/416 , A61L2300/432
摘要： Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
摘要翻译： 包含抗纤维化剂和/或聚合物组合物的组合物可用于各种医学应用，包括预防手术粘连，治疗炎性关节炎，治疗瘢痕和瘢痕疙瘩，治疗血管疾病和预防软骨 失利。
-
公开(公告)号：US20070270447A1
公开(公告)日：2007-11-22
申请号：US11888511
申请日：2007-07-31
申请人： William Hunter , David Gravett , Philip Toleikis , Richard Liggins , Troy Loss
发明人： William Hunter , David Gravett , Philip Toleikis , Richard Liggins , Troy Loss
IPC分类号： A61K31/513 , A61P31/00
CPC分类号： A61L29/16 , A61L27/34 , A61L27/54 , A61L29/085 , A61L2300/404 , A61L2300/416
摘要： Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.
摘要翻译： 提供了释放蒽环类抗生素，氟嘧啶，叶酸拮抗剂，足细胞毒素，喜树碱，羟基脲和/或铂络合物的医学植入物，从而抑制或降低与植入相关的感染的发生率。
-
公开(公告)号：US20060240063A9
公开(公告)日：2006-10-26
申请号：US11001421
申请日：2004-12-01
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61F2/28
CPC分类号： A61L27/54 , A61B17/11 , A61B17/12022 , A61B17/12099 , A61B17/12109 , A61B17/1214 , A61B17/12168 , A61B17/12186 , A61B17/1219 , A61B17/68 , A61F2250/0067 , A61K38/363 , A61K38/38 , A61K38/39 , A61K38/4833 , A61K45/06 , A61L31/16 , A61L2300/00 , A61L2300/412 , A61L2430/38 , A61K2300/00
摘要： Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
-
公开(公告)号：US20050191331A1
公开(公告)日：2005-09-01
申请号：US11001419
申请日：2004-11-30
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61F2/00 , A61F2/02 , A61F2/04 , A61F2/06 , A61F2/28 , A61F2/44 , A61K38/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M16/04 , A61M31/00 , A61N1/05 , A62B9/00
CPC分类号： A61L31/16 , A61B17/11 , A61B17/12022 , A61B17/1219 , A61F2250/0067 , A61L2300/404 , A61L2300/406 , A61L2300/416 , A61L2300/426 , A61L2300/432 , A61N1/05
摘要： Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
-
-
-
-
-
-
-
-
-
搜索结果
57 条记录 (耗时 0.186 秒)
